Gainers & Losers
Mon Nov 25 2024 10:23:34- Larsen & Toubro share price
- ₹3,753.254.13%
- State Bank Of India share price
- ₹844.753.52%
- HDFC Bank share price
- ₹1,784.602.21%
- Wipro share price
- ₹582.751.99%
- ICICI Bank share price
- ₹1,301.501.82%
Active Stocks
Mon Nov 25 2024 10:27:51- Adani Power share price
- ₹446.85-3.02%
- Power Grid Corporation Of ...
- ₹342.851.74%
- Tata Steel share price
- ₹143.600.56%
- State Bank Of India share price
- ₹844.753.52%
- HDFC Bank share price
- ₹1,784.602.21%
Business News/Market/Market Stats/Glenmark Pharmaceuticals share price/ Glenmark Pharmaceuticals Profit Loss Annual
Glenmark Pharmaceuticals Profit & Loss Annual
Trade1,493.45 +13.40 (0.91%)Updated : 25 Nov 2024
| Fiscal Period | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
| Revenue | 11,813.10 | 11,583.24 | 12,304.90 | 10,943.93 |
| Total Revenue | 11,813.10 | 11,583.24 | 12,304.90 | 10,943.93 |
| Costof Revenue Total | 4,413.37 | 4,257.54 | 4,978.81 | 4,327.18 |
| Gross Profit | 7,399.73 | 7,325.70 | 7,326.09 | 6,616.75 |
| Selling/ General/ Admin Expenses Total | 2,868.14 | 2,600.78 | 3,374.22 | 3,242.35 |
| Depreciation/ Amortization | 581.91 | 569.17 | 486.72 | 443.55 |
| Unusual Expense( Income) | 900.96 | 765.85 | 260.91 | -44.55 |
| Other Operating Expenses Total | 3,336.25 | 3,089.92 | 1,625.11 | 1,290.01 |
| Total Operating Expense | 12,100.63 | 11,283.26 | 10,725.77 | 9,258.56 |
| Operating Income | -287.53 | 299.98 | 1,579.14 | 1,685.37 |
| Interest Inc( Exp) Net- Non- Op Total | -5,159.69 | -3,490.36 | -1,508.05 | -3,342.16 |
| Other Net | 839.99 | 288.90 | 19.38 | 30.97 |
| Net Income Before Taxes | 36.50 | 239.84 | 1,441.25 | 1,382.48 |
| Provisionfor Income Taxes | 1,867.35 | 329.40 | 447.60 | 412.39 |
| Net Income After Taxes | -1,830.85 | -89.56 | 993.65 | 970.09 |
| Minority Interest | -68.15 | -80.16 | -51.94 | - |
| Net Income Before Extra Items | -1,899.00 | -169.72 | 941.71 | 970.09 |
| Total Extraordinary Items | 397.33 | 466.96 | - | - |
| Net Income | -1,501.67 | 297.25 | 941.71 | 970.09 |
| Income Availableto Com Excl Extra Ord | -1,899.00 | -169.72 | 941.71 | 970.09 |
| Income Availableto Com Incl Extra Ord | -1,501.67 | 297.25 | 941.71 | 970.09 |
| Diluted Net Income | -1,501.67 | 297.25 | 941.71 | 970.09 |
| Diluted Weighted Average Shares | 28.22 | 28.23 | 28.22 | 28.22 |
| Diluted EPS Excluding Extra Ord Items | -67.30 | -6.01 | 33.37 | 34.38 |
| DPS- Common Stock Primary Issue | 2.50 | 2.50 | 2.50 | 2.50 |
| Diluted Normalized EPS | -46.55 | 11.62 | 39.91 | 33.26 |
| Gain( Loss)on Saleof Assets | - | - | -64.64 | 3.54 |
*All figures in crores except per share values
Glenmark Pharmaceuticals Quick Links
Glenmark Pharmaceuticals Dividend Glenmark Pharmaceuticals Bonus Glenmark Pharmaceuticals News Glenmark Pharmaceuticals AGM Glenmark Pharmaceuticals Rights Glenmark Pharmaceuticals Splits Glenmark Pharmaceuticals Board Meetings Glenmark Pharmaceuticals Key Metrics Glenmark Pharmaceuticals Shareholdings Glenmark Pharmaceuticals Balance Sheet Glenmark Pharmaceuticals Cashflow Glenmark Pharmaceuticals Q1 Results Glenmark Pharmaceuticals Q2 Results Glenmark Pharmaceuticals Q3 Results Glenmark Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
3,753.25+148.70(4.13%)
844.75+28.70(3.52%)
1,784.60+38.65(2.21%)
1,733.95-13.75 (-0.79%)
2,460.60-18.40 (-0.74%)